With a series of new dementia treatments being approved in Korea, whether the market dominated by Aricept will falter is gaining attention. Aricept (donepezil hydrochloride, Eisai Korea) has been dominated the market with an 80% share in the Korean prescription market.

The Ministry of Food and Safety approved Lundbeck Korea’s ‘Ebixa tablet 20mg’ on the 1st. Although Ebixa’s share in the market is much behind Aricept by performance, it is still the single Alzheimer’s treatment that ranks second after Aricept in the Korean market as a single product.

The Ebixa tablet currently in the market is a 10mg formulation and is used to treat moderate-to-severe Alzheimer’s. The maximum daily d